MedTrace Logo

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

NCT07140900 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-05

No results posted yet for this study

Summary

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

DRUG

Xaluritamig

Participants will receive xaluritamig intravenously.

DRUG

Darolutamide

Participants will receive darolutamide orally.

DRUG

Abiraterone

Participants will receive abiraterone orally.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-07
Primary Completion
2028-03-27
Completion
2030-03-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140900 on ClinicalTrials.gov